vTv Therapeutics Inc.: vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
vTv Therapeutics (Nasdaq: VTVT) reported Q2 2026 results for the quarter ended June 30, 2026. The company said Phase 3 CATT1 cadisegliatin enrollment is expected to complete in Q3 2026 and it expects cash of $86.6M at June 30 to fund operations through the CATT1 topline readout. Q2 net loss was $13.1M, or $1.05/share.
How this was made
The 30-second read
Why it matters
The update clarifies near-term execution milestones (Phase 3 enrollment completion in Q3 2026) and reiterates funding runway into anticipated topline data, which can affect perceived execution and dilution risk.
Market read
Traders may adjust expectations for vTv’s next major operational milestone (CATT1 enrollment completion) and reassess dilution risk based on the stated cash runway.
What to watch
Enrollment completion timing can slip in Phase 3; investors may also focus on the magnitude of R&D spend ramp and whether future financing needs emerge before topline.
Background
vTv is advancing cadisegliatin (TTP399), an oral glucokinase activator, in a Phase 3 program (CATT1) for type 1 diabetes as an adjunct to insulin.
Ticker impact
vTv reports Q2 2026 results and says it expects to complete Phase 3 CATT1 enrollment in Q3 2026, with cash funding through topline.
Likely modest positive bias as runway and trial timeline reduce financing and execution risk, but upside depends on eventual topline efficacy/safety.
The article provides concrete operational milestones (enrollment completion in Q3 2026, Phase 2a initiation before year-end 2026) and a cash runway statement, but no new efficacy or regulatory outcome.
Market effects
Adds incremental datapoint on late-stage oral adjunct diabetes pipeline execution and typical biotech financing runway framing.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Limited, as the update is company-specific and focused on US Phase 3 timelines.
Counterpoint
Cash runway through topline is helpful, but without any new clinical efficacy data, the market may still discount the update until topline results.
Key entities
- companyvTv Therapeutics Inc.
Late-stage biopharmaceutical company advancing cadisegliatin for type 1 diabetes.
- drug_programcadisegliatin (TTP399)
Oral small molecule glucokinase activator being studied as an adjunctive therapy in T1D.
- clinical_trialPhase 3 CATT1 trial
Evaluates cadisegliatin as an oral adjunct to insulin in individuals with T1D; enrollment expected to complete in Q3 2026.
- clinical_trialHybrid CATT1 Phase 2a trial
Hybrid closed-loop study expected to initiate before year end 2026 to inform future Phase 3 design.
